Investigational EGFR x HER3 therapy supports Phase III dose after lung cancer trial

An investigational EGFR x HER3 antibody-drug conjugate demonstrated promising efficacy with a tolerable information illustration successful patients with antecedently treated EGFR-mutated non-small compartment lung crab (NSCLC), supporting enactment of the 2.5 mg/kg dose for valuation successful the planetary Phase III IZABRIGHT-Lung01 registrational study.